Bovine viral diarrhea virus (BVDV) is a major pathogen of cattle causing severe respiratory and reproductive disease. Since BVDV infects through the oral-nasal route, increasing mucosal immunity should decrease BVDV infection and disease. This makes parenteral vaccines that can traffic antigens to mucosal lymphoid tissue more advantageous for generating mucosal immunity. This study was aimed at the distribution of bovine viral diarrhea virus (BVDV) in tissues following vaccination with one of three commercial vaccines: two vaccines containing cytopathic (CP) BVDV viruses and one vaccine containing noncytopathic (NCP) BVDV virus.